Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1614 1621 1629
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19299563 | Solid Dispersion Forms of Rifaximin | Non-Final OA | Salix Pharmaceuticals, Inc. |
| 18249948 | ELEVATION OF MITOCHONDRIAL BIOGENESIS AND FUNCTION BY INHIBITION OF PROSTAGLANDIN DEGRADING ENZYME 15-PGDH | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 19258712 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18563694 | Antibacterial Composition | Non-Final OA | LG Chem, Ltd. |
| 19055912 | METHODS OF TREATING MIGRAINE | Non-Final OA | Allergan Pharmaceuticals International Limited |
| 18913492 | METHODS OF TREATING MIGRAINE | Non-Final OA | Allergan Pharmaceuticals International Limited |
| 18030491 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | Non-Final OA | Emory University |
| 18309560 | APPLICATION OF GENISTEIN AND ITS PHOSPHATE ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Non-Final OA | National Taiwan University |
| 18217821 | LIPID EMULSIONS FOR PARENTERAL NUTRITION | Non-Final OA | BAXTER HEALTHCARE SA |
| 18043436 | N-Linked Glycosylation Inhibitors and Methods of Using Same | Non-Final OA | YALE UNIVERSITY |
| 18016131 | METHODS FOR TREATING METASTATIC CANCER USING LOW DOSE CARBON MONOXIDE | Non-Final OA | Cornell University |
| 18762343 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Non-Final OA | Albireo AB |
| 18162859 | SKIN BARRIER FUNCTION IMPROVING AGENT | Final Rejection | Kyoto University |
| 18460334 | NOVEL FLUOROCHEMICAL CARDIAC RESUSCITATION | Non-Final OA | NUVOX PHARMA LLC |
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | Non-Final OA | Aslan Pharmaceuticals Pte Ltd |
| 17767742 | METHOD FOR SELECTING, ASSESSING, OR PRODUCING SODIUM LAURYL SULFATE AS RAW MATERIAL FOR PHARMACEUTICAL FORMULATION, OR FORMULATION OR THE LIKE CONTAINING SAME | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18602013 | COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS | Non-Final OA | Fleurir ABX LLC |
| 18251827 | PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18027888 | ARYLAZABICYCLO[2.1.1]HEXYLMETHANOLS DERIVATIVES AND MEDICAL USES THEREOF | Non-Final OA | ATROGI AB |
| 17782440 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Non-Final OA | PHARMANUTRA S.P.A |
| 18272769 | MEDICINE COMPRISING GLYCOPYRRONIUM SALICYLATE | Non-Final OA | SANWA KAGAKU KENKYUSHO CO., LTD. |
| 17493160 | Methods Of Treating Overweight And Obesity | Non-Final OA | Nalpropion Pharmaceuticals LLC |
| 17909163 | COMPOSITION FOR POLYAMINE BIOSYNTHESIS | Non-Final OA | BM Health GmbH |
| 17482364 | Post Cov19 Vaccine Remedies | Non-Final OA | IPRX, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy